Friday, May 19, 2013
Exclusive VideoJoint Session with the Heart Foundation of Australia
Dr. Stephan Fihn, interviewed by Dr. Henry Ting, QCOR Conference Chair
|Stephan Fihn, MD, Department of Veterans Affairs, Seattle, Washington
Plenary III: Electronic Health Records and Research
Newer Developments in EHRs and Research
Elizabeth A. Jackson, MD, MPH
University of Michigan, Ann Arbor, MI
Concurrent III Session B: Women in CVD
Update on Guidelines in Primary Prevention of CVD in Women
Susmita Parashar, MD, MPH
Emory University, Atlanta, GA
Session III B: Women in CVD
Non-invasive CVD Risk Stratification in Women
Science to be Published
|Chronic Kidney Disease and Outcomes in Heart Failure With Preserved Versus Reduced Ejection Fraction (The Cardiovascular Research Network PRESERVE Study)
Authors: David H. Smith, RPh, MHA, PhD; Micah L. Thorp, DO, MPH; Jerry H. Gurwitz, MD; David D. McManus, MD, ScM; Robert J. Goldberg, PhD; Larry A. Allen, MD, MHS; Grace Hsu, MPH; Sue Hee Sung, MPH; David J. Magid, MD, MPH; Alan S. Go, MD
Circulation: Cardiovascular Quality and Outcomes 2013; 6: A301
Cardiovascular Disease Statistics:
- In 2009, the annual direct and indirect cost of CVD and stroke in the United States is an estimated $312.6 billion.
- $192.1 billion was spent on cost of physicians and other professionals, hospital services, prescribed medication, and home health care and $120.5 billion was spent in lost future productivity attributed to prema¬ture CVD and stroke mortality.
- By 2030, 40.8% of the US population is projected to have some form of CVD. Between 2013 and 2030, total direct medical costs of CVD are projected to increase from $320 billion to $818 billion.
- Indirect costs due to lost productivity for all CVDs are estimated to increase from $203 billion in 2013 to $308 billion in 2030, an increase of 52%.